It remains to be determined if the expression of Drp1(-/17) and the concomitant improved mitochondrial function thus grants ovarian cancer cells greater metabolic flexibility and confers survival advantages in the face of shifting nutrient availability, or if an expression of specific Drp1 splice variants can lead to metabolic vulnerabilities that could be harnessed for therapeutic intervention. This evidence concerns the gene DNM1L and ovarian cancer.